"10.1371_journal.pone.0091970","plos one","2014-03-25T00:00:00Z","Pierre Abramowski; Benjamin Otto; Roland Martin","Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims), ZMNH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Research Department Cell and Gene Therapy, Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; I. Department of Internal Medicine, Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Clinical Chemistry, Center for Diagnostic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Neuroimmunology and MS Research, Department of Neurology, University Hospital Zurich, Zurich, Switzerland","Conceived and designed the experiments: PA RM. Performed the experiments: PA. Analyzed the data: PA BO RM. Contributed reagents/materials/analysis tools: BO. Wrote the paper: PA RM.","I have read the journal's policy and have the following conflicts: Some data presented in this study constitute the base for the patent application “Tri-substituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis” (1208850.6). P. Abramowski and R. Martin are shareholders of the CellProtect Holding AG. During the last five years R. Martin has served as advisor or speaker and received personal remuneration from Novartis, Biogen Idec, Teva, Merck AG and Bionamics. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.","2014","03","Pierre Abramowski","PA",3,TRUE,2,1,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
